OPKO Health, Inc. License and Services Revenue (Deprecated 2018-01-31)
OPKO Health, Inc. (OPK) reported License and Services Revenue (Deprecated 2018-01-31) of $5.20 million for the 3-month period ending 2013-06-30, per its 10-Q filed 2013-08-09.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2013-08-09
- OPKO Health, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2013-06-30 was $5.20M, a 1669.73% increase year-over-year.
- OPKO Health, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2013-03-31 was $15.85M, a 11384.78% increase year-over-year.
- OPKO Health, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2012-06-30 was $294.00K.
- OPKO Health, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2012-03-31 was $138.00K.
- OPKO Health, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2012 was $1.75M, a 1195.56% increase from fiscal 2011.
- OPKO Health, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2011 was $135.00K, a 97.99% decline from fiscal 2010.
- OPKO Health, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2010 was $6.73M.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|
| 2013-06-30 | $5.20M 10-Q · filed 2013-08-09 | $21.05M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $15.85M 10-Q · filed 2013-05-10 | ||
| 2012-12-31 | $1.75M 10-K · filed 2013-03-18 | ||
| 2012-06-30 | $294.00K 10-Q · filed 2013-08-09 | $432.00K 10-Q · filed 2013-08-09 | |
| 2012-03-31 | $138.00K 10-Q · filed 2013-05-10 | ||
| 2011-12-31 | $135.00K 10-K · filed 2013-03-18 | ||
| 2010-12-31 | $6.73M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |